Frost & Sullivan invited to attend the 2025 ZAO DX Early Screening Conference

Regarding the current global cancer situation, she stated that lung cancer is the most prevalent cancer globally, with the highest incidence and mortality rates. Moreover, its death toll far exceeds that of other cancers, indicating an unfavorable prognosis and posing a major challenge to global cancer prevention and control. In addition to lung cancer, the top five cancers with high incidence rates include breast cancer, colorectal cancer, prostate cancer, and gastric cancer; the top five cancers with high mortality rates include colorectal cancer, liver cancer, breast cancer, and gastric cancer.

Comparing the ranking of cancers with high incidence and mortality rates, there are significant differences in prognosis among different types of cancer. At the same time, cancers that rank high in both incidence and mortality usually have a poor prognosis, or due to the lack of effective early screening methods, are diagnosed at an advanced stage, posing a major health threat. The high mortality rate of pancreatic cancer directly reflects its malignancy and the great difficulty of clinical treatment. On the other hand, cancers with a relatively high incidence rate but a lower mortality rate benefit from a relatively mature early screening system and effective treatment plans for these types of cancer, significantly extending patients' survival periods and greatly improving survival rates. This current situation provides a clear direction for global cancer prevention and control strategies, and early screening for multiple cancers is imperative.

Cancer screening refers to the process of identifying suspected cancer patients from asymptomatic or symptom-free healthy individuals through certain examination methods, followed by early diagnosis and treatment. This is an important means for early detection and treatment of cancer. The implementation of screening must be determined according to specific conditions, selecting appropriate cancer types and screening methods, and formulating suitable screening plans.

Looking back at the development history of global cancer screening, she believes that the initial development characteristics were: starting with cytological testing for specific cancers, followed by the diversification of technology and its expansion to multiple cancer types. The application of the first screening technology marked the transition from theory to practice in early cancer detection. Screening methods gradually enriched from initial laboratory tests, covering various means such as imaging, enabling cancers like lung cancer, colorectal cancer, and breast cancer to be included in early screening programs. This stage laid the foundational framework for cancer screening, initially demonstrating the potential of screening in reducing cancer mortality, with early screening for multiple cancers becoming a major focus.

At this stage, MCEED is still in the budding and conceptual exploration phase in the strict sense. The research mainly explores the theoretical 'cross-talk' and 'relevance' of biomarkers, which is the most critical first step towards moving from single-cancer thinking to multi-cancer logic, but its transformation prospects are still uncertain.

The development characteristics during the high-speed development period are as follows: frontier technologies represented by methylation detection, mutation signature detection, fragmentation signature detection, and proteomics and metabolomics analysis have achieved diversified breakthroughs, driving the screening paradigm from traditional single-cancer and single-method approaches to broad-spectrum, simultaneous detection based on biomarkers.

Industry consensus is gradually taking shape, with the popularization of concepts prompting capital-intensive entry and intensifying international competition, with Chinese and American companies becoming the main innovators. However, despite the continuous emergence of cutting-edge research findings, their large-scale clinical effectiveness verification, economic evaluation, and the construction of standardized regulatory pathways are generally lagging behind the development speed of the technology itself. Internationally, MCED testing based on whole-genome methylation technology is widely recognized, but its only currently marketed test, Galleri, is still undergoing long-term clinical trials, and its ability to accurately identify tumor locations still needs verification.

Looking at the development history of cancer screening in China, Jing Jing believes that the initial phase of development was characterized by government leadership, focusing on high-incidence areas, regional pilots, and technological catch-up. Compared to developed countries, China's screening practices started significantly later and on a different path. It was only when global evidence-based promotion of traditional single-cancer screening began that systematic work in China was carried out under national planning.

Early screening resources are highly concentrated on high-incidence cancer types in China rather than the key cancer types commonly screened internationally, showing a distinct 'Chinese problem' orientation. The application of technology mainly relies on mature technologies for pilot projects in high-incidence areas, aiming to verify and promote appropriate technical models. This is significantly different from the direction of developed countries exploring cutting-edge molecular markers during the same period.

During the period of rapid development, it can be further divided into two stages: In the first stage, there was a slight divergence between concept advocacy and industry recognition. Although China's cancer screening system has been gradually established under national planning, there are significant differences within the industry regarding the value of screening. Some views are cautious or even skeptical about the clinical effectiveness and cost-effectiveness of emerging screening technologies, believing that their evidence base is not yet sufficient and there is a risk of overdiagnosis.Anpeco BiotechnologyRepresentative local enterprises took the lead in advocating the concept of multi-cancer screening and launched related products as early as 2014. Their strategic choice reflects remarkable foresight.

In the second phase, scientific consensus began to form and validate its value. After 2020, cancer screening in China entered a critical stage driven by high-quality evidence, with industry discussions shifting from 'should screening be done' to 'how to screen more scientifically and efficiently.' MCED officially received authoritative recognition and standardized guidance from the academic community. At the same time, national awareness of early cancer screening has awakened, with demand clearly directed towards more efficient and convenient screening programs. The industry has evolved from early concept advocacy to a new era driven by evidence-based guidelines and precision technology.

Exact SciencesThe CancerSEEK innovative technology based on liquid biopsy was first launched globally in 2018, and its MCED product is widely recognized worldwide. Both are globally renowned enterprises.GrapeleIts MCED product is the world's first commercial multi-cancer test based on whole-genome methylation technology. Chinese companies include BGI Genomics,Sikin MedicalRepresented by Hanapaike Biotech. BGI reported clinical results of MCED products at the ASCO Annual Meeting in 2020, demonstrating its international influence and technological innovation. Similarly, Sichuan Cancer Hospital, which has released MCED products in recent years, is a representative of the emerging forces in cancer screening in China, with frequent research achievements in early cancer screening products. Hanapaike Biotech, as the world's first and China's first company to advocate for the concept and technology of multi-cancer screening, does not rely on chemical characteristic markers for its MCED detection logic, and its related products were released significantly earlier than most global cancer screening companies.

Anpeco Biotechnology's leading position can be traced back to the company's founding philosophy and intellectual property layout, which was significantly ahead of the industry's widespread recognition of this concept in 2010. The related patent for MCED submitted in 2011 further clarified the technical path. In 2014, the world's first technology capable of screening for 16 types of cancer was introduced, completing the leap from a patent concept to a technical product, which was pioneering in the industry.

Subsequently, the accumulation and application of long-term, large-scale real-world data are the cornerstone on which advocates can confidently implement their proposals. As of December 2025, the company has established a database of over 330,000 blood samples, providing indispensable support for its technical effectiveness. At the same time, CDA technology's inclusion in the 'Expert Consensus on Multicancer Combined Screening Based on Liquid Biopsy Technology' reflects its practical depth and has contributed to the formation of industry technical standards. The global intellectual property layout ensures the independence and legality of its technical system on a global scale.

Anpeco Biotechnology's independently developed CDA technology is an emerging technology that does not rely on the detection of chemical characteristic markers. CDA technology has strong early detection signals, making it simpler and less costly compared to traditional detection methods, and is more suitable for general screening and early detection among the general population. The specific advantages are reflected in the following: First, early nature; CDA can detect early-stage cancers including precancerous lesions as well as major diseases; second, convenience; there is no need to fast, and only a 5 ml blood sample is required for testing; third, broad-spectrum nature; a single screening can detect nearly 30 core cancer types; fourth, immediacy; while screening for cancer indicators, it can also reflect the basic physical condition of the subject at the time of testing; fifth, high sensitivity and specificity, with sensitivity and specificity for multiple cancer types reaching over 90% simultaneously; sixth, biosafety, without genetic information, and results can be obtained by detecting biophysical signals. Anpeco Biotechnology has transformed multi-cancer screening from an idea into a practical solution through continuous breakthroughs from technical principles to clinical validation to commercial implementation.